K. Belhadj

发表

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

B. Pégourié, M. Mohty, P. Moreau, 2018, Blood.

Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma

A. Luciani, C. Haioun, E. Itti, 2021, European Radiology.

Clinical and biological features of t(4;14) multiple myeloma: a prospective study

R. Porcher, J. Soulier, M. Macro, 2011, Leukemia & lymphoma.

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

C. Copie-Bergman, J. Jais, A. Rahmouni, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3).

B. Coiffier, O. Casasnovas, P. Feugier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.

B. Pégourié, S. Chevret, M. Macro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mediastinal lymphoma: quantitative changes in gadolinium enhancement at MR imaging after treatment.

P. Gaulard, A. Rahmouni, É. Lepage, 2001, Radiology.

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

R. Bouabdallah, A. Stamatoullas, S. Mareschal, 2016, Bone Marrow Transplantation.

Rituximab, alkylating agents or combination therapy for gastric mucosa‐associated lymphoid tissue lymphoma: a monocentric non‐randomised observational study

A. Amiot, I. Sobhani, C. Copie-Bergman, 2014, Alimentary pharmacology & therapeutics.

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

C. Copie-Bergman, A. Rahmouni, C. Gisselbrecht, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase

E. Solary, C. Chastang, D. Coso, 2002, Leukemia.

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

P. Sonneveld, M. Mohty, M. Béné, 2021, The Lancet. Oncology.

Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma.

A. Amiot, I. Sobhani, C. Copie-Bergman, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.

M. Stegall, S. Knechtle, P. Grimbert, 2019, Journal of the American Society of Nephrology : JASN.

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis

A. Maarek, A. Moktefi, T. Damy, 2022, EJHaem.

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

P. Moreau, S. Minvielle, H. Avet-Loiseau, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P. Sonneveld, M. Béné, M. Vekemans, 2019, The Lancet.

Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation.

F. Zannad, F. Brunotte, Y. Juillière, 1987, The American journal of cardiology.

Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients.

M. Mohty, P. Moreau, S. Minvielle, 2020, Blood.

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

M. Mohty, H. Avet-Loiseau, M. Macro, 2019, Haematologica.

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

O. Decaux, M. Mohty, P. Moreau, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful Long‐Term Outcome of the First Combined Heart and Kidney Transplant in a Patient with Systemic AL Amyloidosis

L. Salomon, C. Haioun, P. Grimbert, 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

N. Munshi, P. Richardson, P. Moreau, 2017, The New England journal of medicine.

T-Cell/Histiocyt e-Rich L arge B -Cell L ymphomas a nd C lassical Diffuse L arge B -Cell L ymphomas H ave S imilar O utcome A fter Chemotherapy: A M atched-Control A nalysis

T. Molina, P. Gaulard, R. Bouabdallah, 2003 .

Hepatosplenic γδ T-cell Lymphoma is a Rare Clinicopathologic Entity with Poor Outcome : Report on a Series of 21 Cases . Short title : HEPATOSPLENIC γδ T-CELL LYMPHOMA

P. Gaulard, H. Tilly, E. Labouyrie, 2003 .

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.

B. Coiffier, O. Casasnovas, H. Tilly, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.

B. Coiffier, H. Tilly, N. Brousse, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colonic mucosa-associated lymphoid tissue lymphoma: a case series

A. Amiot, I. Sobhani, C. Copie-Bergman, 2019, Leukemia & lymphoma.

Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution.

P. Gaulard, A. Rahmouni, C. Haioun, 2005 .

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

J. Soulier, S. Chevret, J. Tamburini, 2015, Haematologica.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

B. Pégourié, O. Decaux, M. Mohty, 2016, Blood.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2016, Blood.

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

P. Sonneveld, M. Béné, P. Moreau, 2022, Haematologica.

P. Moreau, M. Macro, X. Leleu, 2020, Leukemia & lymphoma.

Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma

A. Amiot, I. Sobhani, C. Copie-Bergman, 2017, Leukemia & lymphoma.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

T. Willis, B. Pégourié, P. Richardson, 2018, Blood.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Sebban, 2010, Blood.

Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study

A. Amiot, I. Sobhani, C. Copie-Bergman, 2013, Leukemia & lymphoma.

Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma.

A. Luciani, C. Copie-Bergman, A. Rahmouni, 2017, Radiology.

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.

P. Moreau, X. Leleu, C. Touzeau, 2021, Blood.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Gammadelta T-cell lymphomas.

P. Gaulard, F. Reyes, K. Belhadj, 2003, Seminars in hematology (Print).

Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma

A. Oriol, P. Moreau, M. Macro, 2018, Blood.

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Kr

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2016 .

Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics

C. Copie-Bergman, P. Gaulard, S. Swerdlow, 2012, The American journal of surgical pathology.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

O. Decaux, M. Mohty, P. Moreau, 2022, Haematologica.

A Prospective Phase II Trial of Lenalidomide and Dexamethasone ( LEN-DEX) in POEMS Syndrome

O. Decaux, M. Cogné, P. Moreau, 2014 .

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

N. Munshi, P. Richardson, P. Moreau, 2015 .

A new case of signet ring cell carcinoma of the prostate.

M. Chebil, N. Kourda, K. Belhadj, 2007, Clinical genitourinary cancer.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

D. Dunson, I. Lossos, W. Chan, 2017, Cancer discovery.

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.

C. Copie-Bergman, M. Baia, T. Molina, 2015, Blood.

l'Adulte (GELA) trials first-line polychemotherapy within the Groupe d'Etude des Lymphomes de with NK/T-cell lymphoma : results of a Western series of 48 patients treated Expression of the granzyme B inhibitor PI9 predicts outcome in nasal

F. Berger, C. Gisselbrecht, J. Bosq, 2013 .

Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

P. Gaulard, F. Berger, C. Gisselbrecht, 2007, Blood.

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

N. Munshi, P. Richardson, O. Decaux, 2020 .

Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.

P. Gaulard, C. Haioun, F. Reyes, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

P. Gaulard, H. Tilly, E. Labouyrie, 2003 .

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

P. Gaulard, H. Tilly, E. Labouyrie, 2003, Blood.

T-Cell Lymphomas

P. Gaulard, F. Reyes, K. Belhadj, 2003 .

Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population

C. Cordonnier, D. Bories, K. Belhadj, 2001, Bone Marrow Transplantation.

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients

J. Dupuis, K. Belhadj, B. Maître, 2013, European Respiratory Review.

Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

M. Mohty, P. Moreau, H. Avet-Loiseau, 2021, Leukemia.

Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis.

J. Deux, E. Itti, A. Moktefi, 2019, Mayo Clinic proceedings.

Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma.

J. Roujeau, M. Bagot, N. Ortonne, 2009, Archives of dermatology.

Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).

B. Pégourié, O. Decaux, X. Leleu, 2017 .

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

F. Jardin, P. Gaulard, H. Tilly, 2021, Leukemia & lymphoma.

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

G. Salles, O. Casasnovas, P. Feugier, 2011, Haematologica.

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

Emmanuel Itti, Michel Meignan, Felix Reyes, 2005, Blood.

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

R. Houot, G. Salles, P. Feugier, 2013, Haematologica.

Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case-Control Comparison With Intravenous Rituximab.

A. Amiot, I. Sobhani, C. Copie-Bergman, 2020, Clinical lymphoma, myeloma & leukemia.

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.

P. Feugier, S. Leprêtre, B. Grosbois, 2004, Blood.

Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.

P. Gaulard, B. Quesnel, C. Gisselbrecht, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

lymphocytic leukemia treatment on peripheral blood stem cell mobilization in B-cell chronic Impact of frontline fludarabine and cyclophosphamide combined

S. Leprêtre, B. Grosbois, A. Delmer, 2013 .

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

E. Thiel, B. Coiffier, R. Herrmann, 2004, Clinical Cancer Research.

Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

A. Luciani, A. Rahmouni, C. Haioun, 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.

T. Molina, P. Gaulard, R. Bouabdallah, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging.

P. Gaulard, A. Rahmouni, É. Lepage, 2003, Radiology.

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

P. Sonneveld, P. Moreau, X. Leleu, 2019, Blood.

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

N. Munshi, P. Richardson, M. Faham, 2015 .

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

M. Dimopoulos, H. Eom, R. Schots, 2016, Haematologica.

Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging.

A. Luciani, A. Rahmouni, C. Cuénod, 2015, Radiology.

Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.

A. Luciani, A. Rahmouni, J. Deux, 2010, Radiology.

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

B. Coiffier, J. Jais, O. Casasnovas, 2007 .

Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma.

C. Copie-Bergman, P. Brugières, C. Haioun, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

B. Coiffier, O. Casasnovas, P. Feugier, 2008 .

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

P. Sonneveld, P. Moreau, T. Facon, 2021, Haematologica.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

P. Sonneveld, G. Merlini, M. Minnema, 2021, HemaSphere.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

M. Mohty, P. Moreau, F. Magrangeas, 2015, Blood.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

N. Munshi, M. Mohty, P. Moreau, 2015, Blood.

Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma

A. Oriol, P. Moreau, M. Macro, 2019, Clinical Lymphoma Myeloma and Leukemia.

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

M. Mohty, H. Avet-Loiseau, M. Macro, 2020, Haematologica.

MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study

O. Bernard, V. Ribrag, C. Quivoron, 2023, Cancers.

for the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

R. Houot, G. Salles, P. Feugier, 2013 .

Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients.

P. Gaulard, A. Rahmouni, C. Haioun, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

F. Lemonnier, C. Haioun, S. Gallien, 2022, Clinical Microbiology and Infection.

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

B. Pégourié, P. Moreau, M. Macro, 2017 .

Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide

J. Soulier, P. Moreau, T. Facon, 2008 .

Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.

A. Jaccard, T. Damy, S. Guendouz, 2017, European journal of cancer.

Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma

Alexandre Vignaud, Pierre Brugières, Emmanuel Itti, 2010, European Radiology.

FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma.

J. Soulier, P. Moreau, M. Macro, 2007 .

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

P. Moreau, M. Macro, X. Leleu, 2023, British Journal of Haematology.

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

J. Soulier, I. Yakoub-Agha, P. Moreau, 2010, Leukemia.

Efficiency of In Vivo Purging With Rituximab Followed by High-Dose Therapy With Autologous Peripheral Blood Stem Cell Transplantation in B-Cell Non-Hodgkin’s Lymphomas: A Single-Institution Study

P. Gaulard, C. Haioun, F. Reyes, 2001 .

Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience.

A. Luciani, A. Rahmouni, J. Deux, 2009, Radiology.

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

O. Decaux, M. Mohty, P. Moreau, 2022, Haematologica.

Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis

F. Lemonnier, C. Haioun, A. Maarek, 2021, British journal of haematology.

Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment

F. Lemonnier, C. Haioun, A. Maarek, 2020, Leukemia & lymphoma.

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

L. Frenzel, W. Cuccuini, B. Arnulf, 2020, British Journal of Haematology.

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

B. Coiffier, O. Casasnovas, H. Tilly, 2006 .

Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.

F. Lemonnier, C. Haioun, A. Maarek, 2019, Journal of Clinical Oncology.

Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort

A. Vekhoff, O. Decaux, N. Texier, 2021, Blood.

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, T. Facon, 2019, HemaSphere.

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

G. Gudi, C. Huff, M. Mohty, 2022, Blood.

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

P. Moreau, M. Macro, X. Leleu, 2018, Blood.

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2015 .

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

A. De la taille, C. Duvoux, E. Teiger, 2022, Transplantation direct.

Thrombospondin type-1 domain-containing 7A-related membranous nephropathy associated with glomerular AL amyloidosis.

A. Moktefi, J. Goujon, M. Verpont, 2021, Pathology.

Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group